Published in J Med Chem on March 11, 2010
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod (2010) 1.20
Tanshinones: sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci (2012) 1.08
Antitumor agents 278. 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs as potent in vitro anti-cancer agents. Bioorg Med Chem Lett (2010) 0.96
Discovery of new anticancer agents from higher plants. Front Biosci (Schol Ed) (2012) 0.92
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem (2011) 0.91
Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent. J Nat Prod (2010) 0.83
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future Med Chem (2013) 0.80
Recent Progress of Research on Herbal Products Used in Traditional Chinese Medicine: the Herbs belonging to The Divine Husbandman's Herbal Foundation Canon ( Shén Nóng Běn Cǎo Jīng). J Tradit Complement Med (2012) 0.77
Antitumor agents 287. Substituted 4-amino-2H-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity. Bioorg Med Chem Lett (2011) 0.76
Antitumor agents 279. Structure-activity relationship and in vivo studies of novel 2-(furan-2-yl)naphthalen-1-ol (FNO) analogs as potent and selective anti-breast cancer agents. Bioorg Med Chem Lett (2010) 0.75
Antitumor agents 273. Design and synthesis of N-alkyl-thiocolchicinoids as potential antitumor agents. Bioorg Med Chem Lett (2010) 0.75
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods (1989) 9.42
Drug discovery from medicinal plants. Life Sci (2005) 4.26
New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev (2007) 2.15
Plant-derived compounds in clinical trials. Drug Discov Today (2007) 1.98
Biodiversity as a source of anticancer drugs. Curr Drug Targets (2006) 1.88
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev (2008) 1.82
Natural products in the process of finding new drug candidates. Curr Med Chem (2004) 1.76
Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J Med Chem (2004) 1.64
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol (2008) 1.37
Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J Cardiol (2008) 1.36
Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J Med Chem (2006) 1.29
Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents. J Med Chem (2009) 1.11
Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat (2008) 0.93
Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer. Drugs (2007) 0.92
Highly efficient alkylation to ketones and aldimines with Grignard reagents catalyzed by zinc(II) chloride. J Am Chem Soc (2006) 0.92
Synthesis and evaluation of molluscicidal and larvicidal activities of some novel enaminones derived from 4-hydroxyquinolinones: part IX. Bioorg Med Chem (2005) 0.87
New heterocyclic precursors for thermal generation of reactive, electron-rich 1,2-diaza-1,3-butadienes. Org Lett (2001) 0.87
Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4. Bioorg Med Chem (2006) 0.86
Annulation strategies for benzo[b]fluorene synthesis: efficient routes to the kinafluorenone and WS-5995 antibiotics. J Org Chem (2000) 0.82
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev (2002) 3.49
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell (2007) 3.42
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (2006) 3.26
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
The divergent Robo family protein rig-1/Robo3 is a negative regulator of slit responsiveness required for midline crossing by commissural axons. Cell (2004) 3.19
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res (2005) 2.58
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res (2004) 2.48
Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol (2006) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33
NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A (2004) 2.33
Uteroplacental insufficiency increases apoptosis and alters p53 gene methylation in the full-term IUGR rat kidney. Am J Physiol Regul Integr Comp Physiol (2003) 2.31
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol (2005) 2.30
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol (2005) 2.20
Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes (2010) 2.19
New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev (2007) 2.15
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell (2009) 2.14
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 2.11
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res (2007) 2.10
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
Syntheses and characterizations of three-dimensional channel-like polymeric lanthanide complexes constructed by 1,2,4,5-benzenetetracarboxylic acid. Inorg Chem (2002) 2.05
Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res (2007) 2.02
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des (2003) 2.01
Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab (2010) 2.00
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst (2002) 1.95
Regulatory network of microRNA399 and PHO2 by systemic signaling. Plant Physiol (2008) 1.93
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev (2003) 1.90
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem (2003) 1.88
Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res (2008) 1.88
Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene (2007) 1.86
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell (2009) 1.85
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog (2006) 1.78
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res (2004) 1.76
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol (2006) 1.75
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res (2009) 1.74
Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res (2009) 1.74
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. Bioorg Med Chem (2005) 1.71